In Brief: Nitisinone (Orfadin) for Hereditary Tyrosinemia

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: Subscriptions, Site Licenses, Reprints
or call customer service at: 800-211-2769
IN BRIEF

Nitisinone Oral Suspension (Orfadin) for Hereditary Tyrosinemia

The FDA has approved an oral suspension formulation of nitisinone (Orfadin – Sobi) for treatment of hereditary tyrosinemia type 1 (HT-1). Orfadin has been available in a capsule formulation in Canada since 1994 and in the US since 2002.

HT-1 is an autosomal recessive genetic disorder (estimated birth prevalence: 1:100,000) caused by mutations in the gene responsible for formation of fumarylacetoacetate hydrolase (FAH), which catalyzes the last step in tyrosine metabolism. FAH deficiency results in accumulation of upstream toxic metabolites, causing liver and kidney failure and developmental delays. Before the advent of liver transplantation, HT-1 was invariably fatal, usually as a result of liver failure or hepatocellular carcinoma. Quebec, Canada, which has a relatively high incidence of HT-1, has screened newborns for the disorder since 1970.1

Nitisinone inhibits 4-hydroxyphenylpyruvate dioxygenase, preventing formation of upstream toxic metabolites. Started in infancy in combination with a tyrosine- and phenylalanine-restricted diet, it can prevent development of liver and kidney disease and the need for liver transplantation.2-4

The recommended starting dosage of nitisinone is 0.5 mg/kg twice daily. The dosage can be increased after one month to 0.75 mg/kg twice daily (max 1 mg/kg twice daily). A 30-day supply of Orfadin suspension for a child weighing 10 kg costs $13,623. Orfadin capsules can be opened and the contents can be mixed in a small amount of water, formula, or applesauce. A 30-day supply of Orfadin capsules (60 5-mg capsules) costs $12,499.5

5. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. September 5, 2016. Reprinted with permission by First Databank, Inc. All rights reserved. ©2016. www.fdbhealth.com/policies/drug-pricing-policy.